Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Hologic, Inc. $1 Billion Senior Notes Offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S reopening by…
Davis Polk Advises TiGenix on Its Acquisition by Takeda
Davis Polk is advising TiGenix in connection with its entry into an offer and support agreement with Takeda Pharmaceutical…
Denali Therapeutics Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of…
Revance Therapeutics, Inc. $190 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock…
Editas Medicine, Inc. $50 Million Follow-On Offering
Davis Polk advised the sole book-running manager in connection with the $50 million follow-on offering of 1,970,000…
Aetna $77 billion acquisition by CVS Health
Davis Polk is advising Aetna on its approximately $77 billion acquisition by CVS Health. The transaction, which is expected…
Anthem, Inc. Cash Tender Offers
Davis Polk advised the dealer managers in connection with cash tender offers for (i) any and all of Anthem’s 7.000%…
Anthem, Inc. $5.5 Billion Senior Notes Offering
Davis Polk advised the representatives of the several underwriters on an SEC-registered offering by Anthem, Inc. of $5…
Alnylam Pharmaceuticals, Inc. $805 Million Common Stock Offering
Davis Polk advised the underwriters of an $805 million SEC-registered offering of 6,440,000 shares of common stock of…
Davis Polk Advises Roche on Its €250 Million Cash Tender Offer
Davis Polk advised Roche Holdings, Inc. as to U.S. law in connection with its cash tender offer for up to €250 million…